Korea Seeks New Law To Support Orphan Drugs, Ease Supply Disruptions
This article was originally published in PharmAsia News
Amid continued disruptions in medicine supplies and growing need to develop orphan drugs, South Korea’s government plans to submit a bill to parliament that will enable it to designate "innovative medicines" for the treatment of fatal or incurable diseases, help speed up the development and approval of innovative drugs, as well as ease supply disruptions.
You may also be interested in...
South Korea unveils measures to stabilize supply of essential drugs – including a list of the drugs to monitor, stockpile and manage – to deal with public health crises in time and guarantee treatment opportunities for the nation.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.